A toxicological evaluation of monomethylsilanetriol (MMST) stabilized in acacia gum, a novel silicon preparation.


Journal

Regulatory toxicology and pharmacology : RTP
ISSN: 1096-0295
Titre abrégé: Regul Toxicol Pharmacol
Pays: Netherlands
ID NLM: 8214983

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 06 03 2020
revised: 25 06 2020
accepted: 01 09 2020
pubmed: 10 9 2020
medline: 9 7 2021
entrez: 9 9 2020
Statut: ppublish

Résumé

Monomethylsilanetriol (MMST), a silicon-containing compound, has been sold in dietary supplements. However, toxicological studies on its safety profile are not readily available. To assess the safety of MMST stabilized in acacia gum, a novel delivery form of MMST, in accordance with internationally accepted standards, the genotoxic potential and repeated-dose oral toxicity of Living Silica® Acacia Gum Stabilized Monomethylsilanetriol (formerly known as Orgono Acacia Gum Powder®), a food grade product consisting of 80 ± 10% acacia gum and 2.8% (SD ± 10%) elemental silicon from MMST, was investigated. A bacterial reverse mutation test, an in vitro mammalian chromosomal aberration test, an in vivo mammalian micronucleus test, and a 90-day repeated-dose oral toxicity study in rats were performed. No evidence of mutagenicity or genotoxic activity was observed under the applied test systems. In the 90-day study, male and female Hsd.Han Wistar rats were administered daily doses of 0, 500, 1000, and 2000 mg/kg bw/day by gavage. No mortality or treatment-related adverse effects were observed, and no target organs were identified. Therefore, the no observed adverse effects level (NOAEL) was determined as 2000 mg/kg bw/day (201 mg MMST/kg bw/day), the highest dose tested.

Identifiants

pubmed: 32905813
pii: S0273-2300(20)30208-7
doi: 10.1016/j.yrtph.2020.104782
pii:
doi:

Substances chimiques

Gum Arabic 9000-01-5
Silicon Z4152N8IUI

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104782

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Kayla E Preece (KE)

AIBMR Life Sciences, Inc, 1425 Broadway, Suite 458, Seattle, WA, 98122, USA. Electronic address: kayla@aibmr.com.

Róbert Glávits (R)

Toxi-Coop Zrt, Magyar Jakobinusok tere 4/B, H-1122, Budapest, Hungary. Electronic address: glavits.robert.dr@gmail.com.

Tim Murbach (T)

AIBMR Life Sciences, Inc, 1425 Broadway, Suite 458, Seattle, WA, 98122, USA. Electronic address: tim@aibmr.com.

John R Endres (JR)

AIBMR Life Sciences, Inc, 1425 Broadway, Suite 458, Seattle, WA, 98122, USA. Electronic address: john@aibmr.com.

Gábor Hirka (G)

Toxi-Coop Zrt, Magyar Jakobinusok tere 4/B, H-1122, Budapest, Hungary. Electronic address: gabor.hirka@toxicoop.com.

Adél Vértesi (A)

Toxi-Coop Zrt, Magyar Jakobinusok tere 4/B, H-1122, Budapest, Hungary. Electronic address: adel.vertesi@toxicoop.com.

Erzsébet Béres (E)

Toxi-Coop Zrt, Magyar Jakobinusok tere 4/B, H-1122, Budapest, Hungary. Electronic address: erzsebet.beres@toxicoop.com.

Ilona Pasics Szakonyiné (IP)

Toxi-Coop Zrt, Magyar Jakobinusok tere 4/B, H-1122, Budapest, Hungary. Electronic address: ilona.pasics@toxicoop.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH